Skip to main navigation

Menu

Overview
News Releases
Events & Presentations
Governance
Financials
- SEC Filings
Stock
- Stock Quote & Chart
- Analyst Coverage
IR Resources

DM1 or Myotonic Dystrophy Type 1

View Publications by Indication

Show all

September 4, 2024

RNA Leaders USA Congress

Advancing the Use of Peptide-Conjugated Oligonucleotides to Target Neuromuscular Disorders: Enhanced Delivery Oligonucleotides for DMD and DM1 2.1 MB

April 9, 2024

14th International Myotonic Dystrophy Consortium

FREEDOM-DM1: Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 for Myotonic Dystrophy Type 1 1.6 MB

September 6, 2023

Myotonia Dystrophy Foundation Conference

PGN-EDODM1 Nonclinical Data Demonstrate Mechanistic and Meaningful Activity for Potential Treatment of Myotonic Dystrophy Type 1 6.3 MB

Stock Information
Information Request
Financial Information
FAQ

Print Page
Email Alerts
RSS Feeds
Contact IR

Request Email Alerts

©

2026 PepGen Inc All Rights Reserved.

Privacy Policy
Cookie Policy
Accessibility